Incyte announced that the European Commission has granted a marketing authorization for Opzelura cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. "Opzelura is the first and only approved treatment in the European Union to offer support for repigmentation in eligible patients with non-segmental vitiligo, a chronic autoimmune disease characterized by depigmentation of skin and reduced quality of life," the company stated.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INCY:
- MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study
- Incyte price target raised to $77 from $76 at Morgan Stanley
- Incyte management to meet with Oppenheimer
- Incyte downgraded to Sector Perform after physician survey at RBC Capital
- Incyte downgraded to Sector Perform from Outperform at RBC Capital
